Ariana Pelosci

Articles

Pembrolizumab Plus Radiation Yields Improvements in T-Cell Infiltration in Early Breast Cancer

December 11th 2025

Patients with early breast cancer who received pembrolizumab plus radiation therapy experienced significant improvements in T-Cell infiltration and promising pCR rates.

Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC

December 10th 2025

Sacituzumab govitecan did not improve PFS per BICR vs chemotherapy after endocrine therapy in hormone-receptor–positive/HER2-negative breast cancer.

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer

December 10th 2025

Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.

MK-1045 Therapy Proves Active, Safe With Dose Modification in Relapsed/Refractory ALL

December 9th 2025

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

Ziftomenib at RP2D Demonstrates High Response Rates for NPM1-Mutated AML

December 8th 2025

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma

December 7th 2025

The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.

TBI-Free Conditioning Maintains Strong Outcomes in Pediatric and Young Adult B-Cell ALL

December 6th 2025

The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.

DESTINY-Breast09 Subgroup Data Show Clinically Meaningful PFS Benefit T-DXd/Pertuzumab in HER2+ Breast Cancer

October 20th 2025

T-DXd plus pertuzumab generated consistent PFS benefits among HER2+ breast cancer subgroups.

Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC

October 19th 2025

Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Sevabertinib Yields Robust Responses in HER2-Mutant Advanced NSCLC

October 17th 2025

Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.

First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC

October 17th 2025

First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.

Zongertinib Displays Activity in Frontline HER2-Mutated NSCLC

October 17th 2025

Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.

Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

September 22nd 2025

Isa-VRd produced a VGPR or better rate of 87.8% in transplant-ineligible newly diagnosed multiple myeloma.

Sonrotoclax Plus Dexamethasone Generates Early Efficacy in R/R Myeloma

September 21st 2025

Sonrotoclax plus dexamethasone was well tolerated and produced early efficacy signals in relapsed/refractory multiple myeloma with t(11;14).

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma

September 19th 2025

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

Fixed-Duration Cevostamab After CAR T-Cell Therapy Is Well Tolerated in Heavily Pretreated Myeloma

September 18th 2025

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Concurrent Durvalumab and Chemoradiotherapy Fails to Provide Survival Advantage in Unresectable, Stage III NSCLC

September 8th 2025

Durvalumab/chemoradiation followed by consolidation durvalumab did not improve OS vs chemoradiation followed by durvalumab in stage III NSCLC.

Venetoclax Plus Azacitidine Fails to Provide OS Advantage in Treatment-Naive, Higher-Risk MDS

September 4th 2025

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.